

IMI consultation on advanced therapies

Response from Yuri D'Alessandra

To whom it may concern.

I am sending a few comments on the recently published concept paper. In my opinion one important missing part concerns the development and characterization of RNA/DNA based therapies. Many studies are shedding light on the possibility to use oligo-based anti-miRNA / anti-(lnc)RNA drugs to block the effects of Viral agents or to contrast the mis-expression of specific miRNAs. A couple of clinical trials concerning the use of miR-122 against HCV are a good example. Short anti-RNA probes could also be the future of RNA-targeting antibiotics against MDR bacteria.

Thus, it could be a good idea to encourage and help the development of actions to better characterize the possible applications of these new therapies.

I am sending these comments entirely on my behalf.

Dr. Yuri D'Alessandra, Ph.D.

Researcher

Immunology and Functional Genomics Unit

Via Parea, 4 - 20138 Milano

W www.cardiologicomonzino.it

Centro Cardiologico Monzino

Monzino Cardiology Centre